Profile data is unavailable for this security.
About the company
Kineta, Inc. is a clinical-stage biotechnology company. The Company has leveraged its expertise in innate immunity and is focused on discovering and developing potentially differentiated immunotherapies that address the mechanisms of cancer immune resistance: immunosuppression, exhausted T cells and poor tumor immunogenicity. Its pipeline of immunotherapies includes KVA12123, which is a monoclonal antibody (mAb), immunotherapy targeting VISTA (V-domain Ig suppressor of T cell activation), and an anti-CD27 agonist mAb immunotherapy. KVA12123 may be an effective immunotherapy for many types of cancer, including non-small cell lung cancer (NSCLC), colorectal cancer (CRC), ovarian cancer (OC), renal cell carcinoma (RCC) and head and neck squamous cell carcinoma. It is also developing an anti-CD27 agonist mAb immunotherapy to address the problem of exhausted T cells. The nominated lead candidate is a fully human mAb that demonstrates nanomolar (nM) binding affinity to CD27 in humans.
- Revenue in USD (TTM)5.16m
- Net income in USD-17.89m
- Incorporated2006
- Employees11.00
- LocationKineta Inc7683 Se 27Th Street, Suite 481MERCER ISLAND 98040United StatesUSA
- Phone+1 (206) 378-0400
- Fax+1 (302) 636-5454
- Websitehttps://kinetabio.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
NuCana PLC (ADR) | 0.00 | -34.33m | 7.42m | 25.00 | -- | 0.6107 | -- | -- | -306.86 | -306.86 | 0.00 | 5.75 | 0.00 | -- | -- | 0.00 | -72.34 | -41.01 | -125.17 | -48.07 | -- | -- | -- | -- | -- | -- | 0.0324 | -- | -- | -- | 13.71 | -- | -21.70 | -- |
Pulmatrix Inc | 11.68m | -8.85m | 7.67m | 22.00 | -- | 0.4033 | -- | 0.6564 | -2.42 | -2.42 | 3.20 | 5.21 | 0.3517 | -- | 17.84 | 531,090.90 | -26.63 | -46.91 | -30.21 | -58.12 | -- | -- | -75.73 | -238.04 | -- | -- | 0.00 | -- | 20.21 | 116.62 | 25.03 | -- | 104.29 | -- |
GlucoTrack Inc | 0.00 | -8.74m | 7.72m | 6.00 | -- | 20.07 | -- | -- | -1.87 | -1.87 | 0.00 | 0.0703 | 0.00 | -- | -- | 0.00 | -520.58 | -94.01 | -2,110.63 | -142.35 | -- | -- | -- | -10,447.96 | -- | -- | 0.3415 | -- | -- | -- | -60.02 | -- | -- | -- |
National Graphite Corp | 0.00 | -1.97m | 7.87m | 0.00 | -- | -- | -- | -- | -0.0221 | -0.0221 | 0.00 | -0.0193 | 0.00 | -- | -- | -- | -11,014.44 | -212.13 | -- | -6,295.18 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -1,432.70 | -- | -- | -- |
Protext Mobility Inc | 750.00 | -2.21m | 7.91m | 4.00 | -- | -- | -- | 10,549.47 | -0.4692 | -0.4692 | 0.00001 | -0.0102 | 0.0405 | -- | -- | -- | -9,400.97 | -1,587.94 | -- | -- | 86.67 | -530.19 | -232,392.00 | -17,498.83 | 0.0002 | -1.36 | -- | -- | -93.98 | -63.09 | 27.35 | -- | -- | -- |
Weed Inc | 0.00 | -5.19k | 7.94m | 2.00 | -- | 73.91 | 202.84 | -- | -0.00001 | -0.00001 | 0.00 | 0.0009 | 0.00 | -- | -- | 0.00 | -0.4942 | -385.93 | -9.56 | -822.37 | -- | -- | -- | -- | -- | -23.03 | 0.5461 | -- | -- | -- | 97.93 | -- | -59.13 | -- |
Virpax Pharmaceuticals Inc | 0.00 | -16.89m | 8.04m | 7.00 | -- | -- | -- | -- | -14.42 | -14.42 | 0.00 | -1.04 | 0.00 | -- | -- | 0.00 | -156.21 | -87.52 | -241.52 | -116.56 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 29.84 | -- | -- | -- |
Moleculin Biotech Inc | 0.00 | -26.82m | 8.09m | 18.00 | -- | 0.3748 | -- | -- | -12.94 | -12.94 | 0.00 | 9.34 | 0.00 | -- | -- | 0.00 | -65.50 | -46.84 | -75.07 | -51.49 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -2.56 | -- | -21.54 | -- |
Jaguar Health Inc | 10.14m | -38.32m | 8.09m | 49.00 | -- | 0.5358 | -- | 0.7979 | -78.64 | -78.64 | 9.90 | 3.18 | 0.1806 | 0.2397 | 8.12 | 206,938.80 | -69.22 | -95.29 | -122.86 | -163.54 | 79.07 | 67.28 | -383.35 | -522.28 | 1.39 | -2.78 | 0.6919 | -- | -18.36 | 17.19 | 12.97 | -- | -- | -- |
Organovo Holdings Inc | 109.00k | -14.67m | 8.12m | 12.00 | -- | 1.58 | -- | 74.50 | -1.62 | -1.62 | 0.0119 | 0.3573 | 0.0082 | -- | 1.18 | 5,450.00 | -110.05 | -54.25 | -138.86 | -58.42 | -- | -- | -13,459.63 | -1,890.16 | 1.96 | -- | 0.00 | -- | -70.54 | -48.78 | 15.00 | -- | -11.87 | -- |
Kineta Inc | 5.16m | -17.89m | 8.15m | 11.00 | -- | -- | -- | 1.58 | -1.55 | -1.55 | 0.4673 | -0.564 | 0.6667 | -- | -- | 469,181.80 | -230.51 | -66.16 | -- | -86.61 | -- | -- | -345.77 | -854.74 | -- | -- | -- | -- | 178.65 | 13.89 | 77.76 | -- | -- | -- |
Cannabis Bioscience Internatnl Hlgs Inc | 56.94m | 6.94m | 8.31m | 389.00 | 0.0015 | 0.0002 | 0.9003 | 0.1459 | 0.5328 | 0.5328 | 4.29 | 4.92 | 0.5917 | 62.81 | 1.45 | 146,384.30 | 7.83 | -- | 11.73 | -- | 31.96 | -- | 13.24 | -- | 0.6856 | 50.75 | 0.0631 | -- | 12.79 | -- | 177.84 | -- | -- | -- |
ELEVAI Labs Inc | 2.18m | -4.62m | 8.50m | 18.00 | -- | 3.14 | -- | 3.89 | -0.2665 | -0.2665 | 0.126 | 0.1435 | -- | -- | -- | 121,351.70 | -- | -- | -- | -- | 67.84 | -- | -211.42 | -- | 1.80 | -- | 0.00 | -- | 123.50 | -- | -138.94 | -- | -- | -- |
CeCors Inc | -100.00bn | -100.00bn | 8.63m | 6.00 | -- | -- | -- | -- | -- | -- | -- | -0.0163 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 22.70 | -- | -- | -- |
ABVC Biopharma Inc | 25.37k | -12.62m | 8.82m | 16.00 | -- | 1.01 | -- | 347.73 | -2.37 | -2.37 | 0.0043 | 0.7284 | 0.002 | -- | 0.0673 | 1,585.63 | -103.15 | -103.38 | -189.31 | -231.54 | -854.20 | 76.25 | -51,218.29 | -2,019.89 | -- | -3.19 | 0.1853 | -- | -84.28 | 85.39 | 35.97 | -- | -- | -- |
Holder | Shares | % Held |
---|---|---|
Armistice Capital LLCas of 31 Mar 2024 | 1.05m | 8.54% |
The Colony Group LLCas of 31 Mar 2024 | 92.40k | 0.75% |
The Vanguard Group, Inc.as of 31 Mar 2024 | 59.33k | 0.48% |
Geode Capital Management LLCas of 31 Mar 2024 | 50.03k | 0.41% |
Citadel Securities LLCas of 31 Mar 2024 | 30.07k | 0.25% |
Millennium Management LLCas of 31 Mar 2024 | 29.24k | 0.24% |
Jane Street Capital LLCas of 31 Mar 2024 | 28.95k | 0.24% |
Two Sigma Securities LLCas of 31 Mar 2024 | 27.65k | 0.23% |
Evergreen Capital Management LLCas of 31 Mar 2024 | 20.85k | 0.17% |
Brighton Jones LLCas of 31 Mar 2024 | 20.65k | 0.17% |